KR920000792A - 저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물 - Google Patents

저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물 Download PDF

Info

Publication number
KR920000792A
KR920000792A KR1019910010600A KR910010600A KR920000792A KR 920000792 A KR920000792 A KR 920000792A KR 1019910010600 A KR1019910010600 A KR 1019910010600A KR 910010600 A KR910010600 A KR 910010600A KR 920000792 A KR920000792 A KR 920000792A
Authority
KR
South Korea
Prior art keywords
molecular weight
heparin
mixture
average molecular
daltons
Prior art date
Application number
KR1019910010600A
Other languages
English (en)
Other versions
KR0185586B1 (ko
Inventor
데브리 로저
Original Assignee
베케르 필리쁘
로오느-푸우랜크 로레르 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9398013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920000792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베케르 필리쁘, 로오느-푸우랜크 로레르 소시에테 아노님 filed Critical 베케르 필리쁘
Publication of KR920000792A publication Critical patent/KR920000792A/ko
Application granted granted Critical
Publication of KR0185586B1 publication Critical patent/KR0185586B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. 헤파린을 구성하고, 헤파린보다 더 낮은 중량평균 분자량을 가지며 2,000달톤 이하 분자량의 쇄9-20% 및 8,000달톤 이상 분자량의 쇄 5-20%를 함유하며, 중량 평균 분자량/수평균 분자량 비가 1.3-1.6인 다당류의 일반 구조를 자니는 설페이트화 다당류의 혼합물.
  2. 제1항에 있어서, 25%이하와 동량의 불순물 더마탄 설페이트를 함유한 혼합물.
  3. 제1항 또는 2항에 있어서, 대략 3,500-대략5,500달톤의 중량 평균 분자량을 가지는 혼합물.
  4. 제1항 내지 3항중 어느 한 항에 있어서, 설페이트화 다당류의 쇄가 그의 하나의 말단에 2-0-설포-4-에노피라노수론산을 가지는 혼합물.
  5. 하기 단계로 구성되는, 헤파린을 구성하고, 헤파린보다 더 낮은 중량 평균 분자량을 가지며 2,000달톤 이하 분자량의 쇄9-20% 및 8,000달톤이상 분자량의 쇄 5-20%를 함유하며, 중량평균 분자량/수 평균분자량 비가 1.3-1.6인 다당류의 일반 구조를 가지는, 설페이트화 다당류의 혼합물을 제조하는 방법.
    -첫번째로, 수성 매질내에서 헤파린을 그의 장쇄 4차 암모늄염으로 전환 시키고, -두번째로, 결과 얻어진 염을 에스테르화하여 9.5-14%의 에스테르화 정도를 가진 에스테르를 형성하며, 및-세번째 단계로, 9.5-14%의 에스 테르화정도를 가진 얻어진 에스테르를 해증합한다.
  6. 제5항에 있어서, 두번째 단계를, 에스테르화한 알콜에 상응하는 염화물과 함께 염소화 유기 용매내에서 실시하는 방법.
  7. 제6항에 있어서, 염화물이 염화벤질이며, 용매가 클로로포름 또는 염화메틸렌인 방법.
  8. 제6항 또는 7항에 있어서, 염소화 유기용매 3-5부피부내 25-45℃의 온도에서, 헤파린 염 1중량부와 염화물 대략 1부피부를 혼합시킴에 의해 에스테르화를 실시하는 방법.
  9. 제8항에 있어서, 온도가 30-40℃인 방법.
  10. 제5항 내지 9항중 어느 한 항에 있어서, 에스테르를 수성용액내 강 염기로 처리함으로써 해중합을 수행하는 방법.
  11. 제10항에 있어서, 염기/에스테르 중량비가 0.05-0.2인 방법.
  12. 제11항에 있어서, 중량비가 0.08-0.15인 방법.
  13. 제10항, 11항 또는 12항에 있어서, 물/에스테르 중량비가 15-30인 방법.
  14. 제10항 내지 13항중 어느 한 항에 있어서, 매질의 온도를 50-70℃의 값으로 조정하고, 반응을 30분-3시간 범위의 기간동안 실시하는 방법.
  15. 제14항에 있어서, 매질의 온도가 55-65℃이며, 반응을 1-2시간동안 실시하는 방법.
  16. 제5항 내지 15항중 어느 한 항에 있어서, 헤파린 출발 원료를, 알콜로 수성 용액으로 부터 첨강시켜 정제하는 방법.
  17. 제1항, 2항, 3항 또는 4항에 청구된 바의 설페이트화 다당류의 혼합물로 구성된 혈전중의 예방 또는 치료를 위한 치료 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910010600A 1990-06-26 1991-06-25 저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물 KR0185586B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9008013A FR2663639B1 (fr) 1990-06-26 1990-06-26 Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
FR9008013 1990-06-26
FR90,08013 1990-06-26

Publications (2)

Publication Number Publication Date
KR920000792A true KR920000792A (ko) 1992-01-29
KR0185586B1 KR0185586B1 (ko) 1999-04-01

Family

ID=9398013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910010600A KR0185586B1 (ko) 1990-06-26 1991-06-25 저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물

Country Status (26)

Country Link
US (1) US5389618A (ko)
JP (1) JP3287363B2 (ko)
KR (1) KR0185586B1 (ko)
AT (1) AT398976B (ko)
AU (1) AU643531B2 (ko)
BE (1) BE1006827A3 (ko)
CA (1) CA2045433C (ko)
CH (1) CH682236A5 (ko)
DK (1) DK176524B1 (ko)
ES (1) ES2036922B9 (ko)
FI (1) FI104490B (ko)
FR (1) FR2663639B1 (ko)
GB (1) GB2245898B (ko)
GR (1) GR1000763B (ko)
HU (1) HU210925B (ko)
IE (1) IE66341B1 (ko)
IL (1) IL98604A (ko)
IT (1) IT1248557B (ko)
LU (1) LU87957A1 (ko)
MX (1) MX25829A (ko)
NL (1) NL194947C (ko)
NO (1) NO304991B1 (ko)
NZ (1) NZ238691A (ko)
PT (1) PT98102B (ko)
SE (1) SE506267C2 (ko)
ZA (1) ZA914869B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38743E1 (en) 1990-06-26 2005-06-14 Aventis Pharma S.A. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
US5707973A (en) * 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
FR2687158B1 (fr) * 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
WO1995009188A1 (fr) * 1993-09-30 1995-04-06 Seikagaku Kogyo Kabushiki Kaisha Antithrombotique
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
AU1594801A (en) * 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
US6608042B2 (en) 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
IL154771A0 (en) * 2000-09-08 2003-10-31 Hamilton Civic Hospitals Res Antithrombotic compositions
WO2002047696A1 (de) 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
EP1423130A1 (en) * 2001-08-28 2004-06-02 Leo Pharma A/S Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
JP4828795B2 (ja) * 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20030236221A1 (en) * 2002-06-20 2003-12-25 Chemi Spa Process for the preparation of esters of heparin
ES2282368T3 (es) * 2002-06-20 2007-10-16 Chemi S.P.A. Procedimiento para la preparacion de esteres de heparina.
FR2844808B1 (fr) * 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP2006515927A (ja) * 2002-12-20 2006-06-08 モメンタ ファーマシューティカルズ インコーポレイテッド 疾患を診断および監視するためのグリカンマーカー
AU2004244756A1 (en) * 2003-06-05 2004-12-16 Centelion Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
US7956046B2 (en) 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
ITMI20031679A1 (it) * 2003-08-29 2005-02-28 Opocrin Spa Processo per la produzione di eparine a basso peso
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
GB0509433D0 (en) * 2005-05-09 2005-06-15 Uni For Milj Og Biovitenskap Method
EP1792621B1 (en) 2005-11-30 2012-04-04 Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni" Orally administrable heparin derivatives
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
CN100436483C (zh) * 2006-05-24 2008-11-26 杭州九源基因工程有限公司 一种依诺肝素钠的纯化生产方法
JP2009538386A (ja) 2006-05-25 2009-11-05 モメンタ ファーマシューティカルズ インコーポレイテッド 低分子量ヘパリン組成物およびその使用
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2283045A1 (en) * 2008-05-20 2011-02-16 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
EP2233145A1 (en) 2009-03-19 2010-09-29 Sanofi-Aventis A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9012229B2 (en) 2011-01-28 2015-04-21 Hangzhou Jiuyuan Gene Engineering Co., Ltd. Capillary electrophoresis method for fine structural analysis of enoxaparin sodium
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
AR085961A1 (es) 2011-04-11 2013-11-06 Sanofi Sa Polisacaridos que poseen dos sitios de union a la antitrombina iii, metodo para prepararlos y composiciones farmaceuticas que los contienen
CN102603925B (zh) * 2012-03-21 2013-12-11 东营天东制药有限公司 一种由粗品肝素钠直接生产依诺肝素钠的方法
CN102603926B (zh) * 2012-03-27 2014-04-30 烟台东诚生化股份有限公司 一种高效价肝素钠制备新工艺
CN102633908A (zh) * 2012-05-02 2012-08-15 雷晓刚 一种高品质超低分子量肝素的制备方法
RU2512768C1 (ru) * 2012-12-18 2014-04-10 Федеральное бюджетное учреждение "Государственный институт кровезаменителей и медицинских препаратов (ФБУ "ГИКиМП") Способ получения низкомолекулярного гепарина
CN103145868B (zh) * 2013-01-07 2015-09-16 中国科学院昆明植物研究所 一种低分子量糖胺聚糖衍生物及其药物组合物和其制备方法与应用
CN103175925B (zh) * 2013-03-20 2014-12-03 山东辰中生物制药有限公司 依诺肝素钠生产过程中肝素苄基酯的酯化率的检测方法
CN103214591B (zh) * 2013-04-12 2015-11-04 中国科学院昆明植物研究所 一种含末端2,5-脱水塔罗糖或其衍生物的低分子量糖胺聚糖衍生物
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
US10668015B2 (en) 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
CN109666086B (zh) * 2018-11-05 2020-12-22 上海宝维医药技术有限公司 一种高纯度肝素季铵盐的制备方法及其应用
JP2022540849A (ja) 2019-07-09 2022-09-20 オプティムヴィア、エルエルシー 抗凝固性多糖類の合成方法
EP4182452A4 (en) 2020-07-14 2024-07-31 Optimvia Llc METHOD FOR THE SYNTHESIS OF NON-ANTICOAGULATING HEPARAN SULFATE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK108622C (da) * 1963-01-18 1968-01-15 Roussel Uclaf Fremgangsmåde til fremstilling af benzylheparinat eller dets alkalimetalsalte.
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
DE3265781D1 (en) * 1981-05-21 1985-10-03 Akzo Nv New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
FR2548672A1 (fr) * 1983-07-04 1985-01-11 Pharmuka Lab Oligosaccharides sulfates et leur utilisation comme medicaments
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
ES2006891A6 (es) * 1988-04-09 1989-05-16 Bioiberica Procedimiento de preparacion de fracciones de oligosacaridos por depolimerizacion quimica controlada de heparina.
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5011919A (en) * 1989-01-30 1991-04-30 Ajorca S.A. Modified heparins and obtention process
IT1243300B (it) * 1990-12-20 1994-05-26 Fidia Spa Derivati dell'eparina

Also Published As

Publication number Publication date
LU87957A1 (fr) 1993-01-15
GB2245898B (en) 1993-10-06
DK124391A (da) 1991-12-27
ES2036922A1 (es) 1993-06-01
IT1248557B (it) 1995-01-19
JPH04226101A (ja) 1992-08-14
NZ238691A (en) 1992-07-28
CA2045433A1 (fr) 1991-12-27
FR2663639B1 (fr) 1994-03-18
AU643531B2 (en) 1993-11-18
SE506267C2 (sv) 1997-11-24
ATA128191A (de) 1994-07-15
IE66341B1 (en) 1995-12-27
NO912485D0 (no) 1991-06-25
JP3287363B2 (ja) 2002-06-04
ITMI911757A1 (it) 1992-12-26
AU7928891A (en) 1992-01-02
IL98604A (en) 1998-08-15
PT98102A (pt) 1992-03-31
IL98604A0 (en) 1992-07-15
ES2036922B9 (es) 2012-07-30
NO912485L (no) 1991-12-27
HU210925B (en) 1995-09-28
NL194947B (nl) 2003-04-01
NL194947C (nl) 2003-08-04
FI104490B (fi) 2000-02-15
GR910100270A (en) 1992-08-25
KR0185586B1 (ko) 1999-04-01
SE9101957D0 (sv) 1991-06-25
GB9113589D0 (en) 1991-08-14
AT398976B (de) 1995-02-27
IE912216A1 (en) 1992-01-01
FR2663639A1 (fr) 1991-12-27
CA2045433C (fr) 2002-07-30
DK176524B1 (da) 2008-07-14
BE1006827A3 (fr) 1995-01-03
ZA914869B (en) 1992-04-29
US5389618A (en) 1995-02-14
FI913101A0 (fi) 1991-06-25
DK124391D0 (da) 1991-06-25
PT98102B (pt) 1998-11-30
HUT57796A (en) 1991-12-30
SE9101957L (sv) 1991-12-27
MX25829A (es) 1993-10-01
ITMI911757A0 (it) 1991-06-26
NO304991B1 (no) 1999-03-15
GR1000763B (el) 1992-12-30
CH682236A5 (ko) 1993-08-13
NL9101049A (nl) 1992-01-16
FI913101A (fi) 1991-12-27
GB2245898A (en) 1992-01-15
ES2036922B1 (es) 1994-03-01

Similar Documents

Publication Publication Date Title
KR920000792A (ko) 저 분자량 다당류 혼합물, 그의 제조 방법 및 그로 구성된 치료 조성물
US4981955A (en) Depolymerization method of heparin
US5010063A (en) Heparin derivatives and process for their preparation
KR900018129A (ko) 콘드로이틴 황산염, 데르마탄황산염 및 히알루론산의 술포아미노 유도체와 그 약제학적 성질
US3247063A (en) Anticoagulants containing heparin and polysaccharides
EP0970130B1 (en) Glycosaminoglycans having high antithrombotic activity
ES2007422A6 (es) Un metodo para modificar alginatos u otros compuestos que contienen acido uronico.
DE69522339D1 (de) Verfahren zur herstellung eines ester von stärke, stärkeester und zusammensetzung die die stärkeester enthalten
ATE106901T1 (de) Verfahren zur depolymerisierung von heparin zum erhalten eines heparins mit niedrigem molekulargewicht und einer antithrombotischen aktivität.
ATE119547T1 (de) Oligosaccharide mit antiatherosclerotischer wirkung.
WO2002050125A3 (en) Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation
DE60002871D1 (de) Verfahren zur herstellung von celluloseethern mit verminderter vergilbung und verfärbung
RU2000100374A (ru) Смеси олигосахаридов, обладающие антитромботической активностью
HUP0002333A2 (hu) Trombózis ellen hatásos oligoszacharidkeverék
ATE388169T1 (de) Niedermolekulare polysaccharide mit antithrombotischer wirkung
US5705493A (en) Oligosaccharides having biological activity and preparation of same from supersulfated dermatan
DK200401720A (da) Blandinger af sulfaterede polysaccharider samt fremstilling og anvendelse deraf
ATE6517T1 (de) Ein chloralderivat, verfahren zur herstellung dieses derivats und eine dieses derivat enthaltende therapeutische zusammensetzung.
DE413248T1 (de) Substanzen mit heparinaehnlicher struktur und verfahren zur herstellung.
US2729633A (en) Sulfated pectic acid blood anticoagulant
US1964017A (en) Utilizing purified musa fiber cellulose
DE933776C (de) Verfahren zur Herstellung blutgerinnungshemmender Stoffe aus phosphorylierten Pektinen
CA2204723A1 (en) Method for producing starch esters, starch esters, and starch ester compositions
RU95110112A (ru) Способ получения хитозан-глюканового комплекса
KR920012156A (ko) 고강도 고광택 섬유형성용 폴리에스테르의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101208

Year of fee payment: 13

EXPY Expiration of term